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For undiagnosed patients and those with rare diseases, the affected individuals themselves 
are an especially critical source of phenotyping information. These patients live with their 
condition and develop explicit and implicit knowledge about it, whether from multiple 
clinician evaluations or from other families and patients experiencing diagnosis for similar 
conditions. From these interactions, they develop a lexicon of relevant terms; these terms are 
frequently in plain language, but can also include clinical terms. In exceptional cases, 
patients’ self-phenotyping and investigations have led to clinical diagnosis; for example, Jill 
Viles, despite skepticism from doctors, managed to not only diagnose herself and her family 
members but also to discover fundamental biology and improved management of autosomal 
dominant Emery–Dreifuss muscular dystrophy1. Further, some phenotypes are not readily 
observed clinically but can be documented by the patient or family; for instance, the Might 
family (NGLY1) observed that their baby did not produce tears when crying, and they used 
this feature to help identify other families with the same disease.
Human genetics and precision medicine aim to understand the relationship between genetic 
variants and diseases. Whole-exome and whole-genome sequencing have transformed the 
ability to comprehensively characterize genetic variants. Although whole-exome and whole-
genome sequencing have led to the discovery of many novel disease-associated genes, the 
diagnostic yield in patients without a clear clinical diagnosis has been 11–25%2. With 
approximately 30,000–100,000 called variants in a typical exome or ~4.5 million variants in 
a typical genome, multiple candidate genes remain after a bioinformatic analysis; additional 
methods and data are needed to refine the list of candidates.
The Human Phenotype Ontology (HPO) was created to enable ‘deep phenotyping’, that is, 
capture of symptoms and phenotypic findings using a logically constructed hierarchy of 
phenotypic terms3. The HPO has become the de facto standard for representing clinical 
phenotype data to inform diagnoses for rare genetic diseases by the 100,000 Genomes 
Project, the NIH Undiagnosed Diseases Program (UDP) and Undiagnosed Diseases Network 
(UDN), and thousands of other clinics, laboratories, tools and databases3–5. The computable 
phenotypic profiles (sets of terms) of individual patients allow imperfect or ‘fuzzy’ matching 
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against the phenotypic profiles of known diseases and model organisms; this matching is 
based on proximity of terms in the hierarchy and on term specificity3,6,7. In comparison to 
using whole-exome or whole-genome sequencing and clinical data alone, we have shown 
that HPO-based phenotyping improves molecular diagnosis in the UDP by 10–20%8.
One of the bottlenecks is that deep phenotyping can be time-consuming and miss key 
phenotypic features not observed clinically. Patients could contribute computable phenotype 
data themselves; however, the ‘terminology gap’ between medical professionals and patients 
is a hindrance. The terminology gap has also limited patient participation both in research 
studies and in clinical phenotyping9. Current patient vocabularies (such as the Consumer 
Health Vocabulary Initiative; see URLs) provide broad consumer equivalents for clinical 
findings, medical procedures and equipment, but are not well integrated with research 
terminologies; thus, they provide neither the structure nor the coverage required for 
translational research and diagnostic tools. While consumer vocabularies and clinical survey 
instruments can be mapped to HPO terms, they tend to provide only high-level phenotype 
terms that are unsuitable for use in clinical genetics contexts. Finally, lay synonyms would 
be very useful to improve information retrieval for patients from the literature.
To address these issues, we sought to make the HPO capable of capturing patient-generated 
phenotypic profiles for use in diagnostic and patient community settings (registries, forums, 
clinics and patient websites). To achieve this, we systematically added patient-centered 
synonyms throughout the HPO by manually reviewing many sources and knowledgebases, 
including Wikipedia, MedlinePlus, the Mayo Clinic, Online Mendelian Inheritance in Man 
(OMIM), the Elements of Morphology and patient forums such as the WebMD message 
board, as well as other ontologies, terminologies and specialty texts. We also made synonym 
creation across terms consistent. For example, ‘increased bone density in 2nd toe bone’ and 
‘increased bone density in 3rd toe bone’, etc., were added as synonyms for ‘sclerosis of the 
2nd toe phalanx’ and ‘sclerosis of the 3rd toe phalanx’, respectively. The synonyms are 
classified as exact, broad, narrow or related according to Open Biological and Biomedical 
Ontology Foundry (see URLs) convention. Synonyms are classified as exact if they can be 
used interchangeably in computational algorithms without loss of precision. For 40% of the 
terms, there exists no reasonable non-clinical language, for example, ‘anomalous origin of 
left coronary artery from the pulmonary artery’ (HP:0011638). Other terms such as 
phenotypes involving the radius and ulna could not be succinctly distinguished in layperson 
terminology (for example, ‘forearm bone’). We also recognized relationships within the 
ontology when adding layperson synonyms: for example, ‘yellowing of the skin’ was added 
to the HPO class ‘jaundice’, but also to subclasses. ‘Intermittent jaundice’, for example, 
would have the lay synonym ‘intermittent yellowing of the skin’,
URLs
Consumer Health Vocabulary initiative, http://consumerhealthvocab.chpc.utah.edu/CHVwiki/; Open Biological and Biomedical 
Ontology Foundry, http://obofoundry.org/; Human Phenotype Ontology, http://purl.obolibrary.org/obo/hp.owl; Phentypr, https://
phenotypr.com/; MyGene2, http://mygene2.org/; HPO browser, http://www.human-phenotype-ontology.org/; National Organization 
for Rare Disorders, https://rarediseases.org/; Genetic and Rare Diseases Information Center, https://rarediseases.info.nih.gov/; FAIR, 
https://www.force11.org/group/fairgroup/fairprinciples.
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We reviewed the population and distribution of lay terms within the HPO and found that the 
major fraction of layperson synonyms were added to very specific terms (for example, 
‘clinodactyly’ rather than ‘abnormality of the digits’), suggesting that they would be specific 
enough to be used diagnostically. In total, 36% of the HPO terms from the most recent 
release (see URLs) have at least one layperson synonym (4,547 of 12,623) (Fig. 1). 89% of 
the diseases (8,666 of 9,657) in the HPO database have at least one HPO annotation with a 
layperson synonym, and 60% of all disease annotations (73,932 of 122,120) are referring to 
HPO terms with lay translations. This further suggests that the laypersonHPO would be 
useful in a diagnostic setting despite incomplete coverage. Further, because the lay 
translation of the HPO uses the same logical infrastructure as the HPO, patient-generated 
phenotyping data can be readily combined with clinical phenotyping data in the context of 
variant prioritization to improve diagnostic rates as well as other analytics such as examining 
expressivity, penetrance and disease progression. Through a recently funded partnership 
with the Patient-Centered Outcomes Research Institute (PCORI), we will perform a formal 
evaluation of the layperson HPO. This will include an informatics comparison against the 
gold-standard HPO used in genomic diagnostics and usability and effective HPO profile 
generation in cohorts of patients with rare diseases.
We envision the layperson HPO as a resource that will allow patients and families to become 
more effective partners in translational research, empowering families to achieve an accurate 
diagnosis, as well as providing opportunities for people to improve the lives of others by 
increasing medical knowledge through their personal perspectives. The laypersonHPO will 
support efforts such as the patient-friendly self-phenotyping tool Phentypr (see URLs); 
MyGene2 (see URLs), which extracts lay synonyms from patient stories; the HPO browser 
(see URLs) for display; the National Organization for Rare Disorders (see URLs) in its 
registry tool; and navigation on the Genetic and Rare Diseases Information Center. Rare 
disease phenotyping data should be as computationally useful and as open aspossible 
(Findable, Accessible, Interoperable and Reusable, FAIR; see URLs). Therefore,we urge 
clinical geneticists, communities of patients with rare diseases, phenotyping tools,registries 
and consumer testing laboratories to help evaluate, adopt and contribute towardwhat we 
think is a critical resource for engaging patients in their own deep phenotyping. Finally, we 
envision that the layperson HPO will enable patients with rare diseases to share their 
phenotyping profiles openly on the web, even in forums such as Facebook. This will allow 
the use of informatics to support open querying for similar patients to improve diagnosis and 
for cohort and community identification globally.
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Figure 1: HPO pipeline.
a, Coverage of HPO terms with plain-language synonyms (terms broken down by 
anatomical system), b, A physician and a patient describe a patient’s phenotype profile in 
different ways but with the same meaning. This constellation of diverse phenotypes is 
common in Marfan syndrome; each has a plain-language equivalent. c, A sub-branch of eye 
phenotypes within the HPO. Terms are structured rigorously, not only in terms of hierarchy 
(as shown) but also in terms of logical definitions (not shown).
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